Corvus Pharmaceuticals Inc (NASDAQ: CRVS)’s stock price has dropped by -4.41 in relation to previous closing price of 3.63. Nevertheless, the company has seen a loss of -3.07% in its stock price over the last five trading days. benzinga.com reported 2025-05-09 that Corvus Pharmaceuticals, Inc. CRVS on Thursday released new interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Is It Worth Investing in Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Right Now?
Moreover, the 36-month beta value for CRVS is 0.55. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRVS is 53.34M and currently, short sellers hold a 10.83% of that float. On May 23, 2025, CRVS’s average trading volume was 1.03M shares.
CRVS’s Market Performance
CRVS stock saw a decrease of -3.07% in the past week, with a monthly decline of -1.42% and a quarterly a decrease of -17.18%. The volatility ratio for the week is 2.65%, and the volatility levels for the last 30 days are 7.52% for Corvus Pharmaceuticals Inc (CRVS). The simple moving average for the past 20 days is -4.32% for CRVS’s stock, with a -34.53% simple moving average for the past 200 days.
Analysts’ Opinion of CRVS
Many brokerage firms have already submitted their reports for CRVS stocks, with H.C. Wainwright repeating the rating for CRVS by listing it as a “Buy.” The predicted price for CRVS in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on January 02, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see CRVS reach a price target of $7. The rating they have provided for CRVS stocks is “Outperform” according to the report published on August 18th, 2023.
Jefferies gave a rating of “Buy” to CRVS, setting the target price at $8 in the report published on December 01st of the previous year.
CRVS Trading at -2.84% from the 50-Day Moving Average
After a stumble in the market that brought CRVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.30% of loss for the given period.
Volatility was left at 7.52%, however, over the last 30 days, the volatility rate increased by 2.65%, as shares sank -5.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.05% lower at present.
During the last 5 trading sessions, CRVS fell by -3.07%, which changed the moving average for the period of 200-days by +23.05% in comparison to the 20-day moving average, which settled at $3.63. In addition, Corvus Pharmaceuticals Inc saw -35.14% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CRVS
The total capital return value is set at -0.62. Equity return is now at value -100.13, with -83.20 for asset returns.
Based on Corvus Pharmaceuticals Inc (CRVS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -24.74.
Currently, EBITDA for the company is -27.55 million with net debt to EBITDA at 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
To wrap up, the performance of Corvus Pharmaceuticals Inc (CRVS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
